BioLineRx (NASDAQ:BLRX) Posts Earnings Results, Beats Expectations By $0.16 EPS

BioLineRx (NASDAQ:BLRX) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.16, Zacks reports. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.49 million. BioLineRx had a negative return on equity of 5.83% and a negative net margin of 99.58%.

Here are the key takeaways from BioLineRx’s conference call:

• GLIX1 IND cleared and first-in-human phase I/II?A trial for glioblastoma is set to start by month-end with patient dosing expected shortly and phase I safety/dose data anticipated in the first half of next year; GLIX1 also has FDA and EMA orphan designations and a key U.S. patent allowance extending protection to 2040.
• Enrollment in the Columbia?led randomized phase IIb PDAC trial of motixafortide (Chemo4METPANC) has accelerated, with a pre?specified interim futility analysis planned once 40% of PFS events occur this year—positive readouts would be a material value inflection.
• The company ended 2025 with approximately $20.9 million in cash, which management says funds operations only into the first half of 2027, even as revenues fell to $1.2M (from $28.9M) — a limited runway that may require future funding or milestone/royalty receipts.
• BioLineRx won a binding arbitration ruling against Biokine, with all claims denied and reimbursement of legal fees awarded, removing a prior financial overhang on the company.
• Investigator data in sickle cell disease showed motixafortide (alone and with natalizumab) was safe and produced robust stem cell mobilization—nearly 3x yields versus prior plerixafor in two subjects—and a second St. Jude study continues to enroll.

BioLineRx Price Performance

Shares of BioLineRx stock traded down $0.03 on Wednesday, hitting $2.40. The company’s stock had a trading volume of 4,830 shares, compared to its average volume of 14,615. The company has a market capitalization of $10.42 million, a price-to-earnings ratio of -14.09 and a beta of 1.31. BioLineRx has a 1 year low of $2.28 and a 1 year high of $7.77. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.93 and a current ratio of 2.09. The firm has a fifty day moving average price of $2.84 and a 200-day moving average price of $3.24.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioLineRx in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $26.00.

BioLineRx Company Profile

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.